Microdosing GLP-1 Medications: Titration, Plateaus, and Finding Your Maintenance Dose

What Is GLP-1 Microdosing?

Microdosing a GLP-1 receptor agonist means injecting a dose smaller than the standard FDA-labeled increment, either temporarily during titration or as a fixed long-term strategy. Clinicians use this approach for two distinct reasons: reducing nausea, vomiting, and gastroparesis-like symptoms that cause early discontinuation, and identifying the personal minimum effective dose that sustains weight loss without pushing to the labeled ceiling. Because compounded semaglutide and compounded tirzepatide are drawn from multi-dose vials, prescribers can specify any dose in increments as small as 0.1 mg, which is not possible with the branded auto-injector pens.

The FDA-approved titration for Wegovy (semaglutide 2.4 mg) is fixed: 0.25 mg for four weeks, 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, then 2.4 mg weekly thereafter [1]. The Zepbound (tirzepatide) label follows a similar logic, starting at 2.5 mg and doubling every four weeks until 5 mg, then increasing by 2.5 mg steps every four weeks to a ceiling of 15 mg [2]. Microdosing strategies, by definition, operate outside these fixed schedules, which means they require close physician oversight and should never be self-directed.

Patients who tolerate standard titration well and reach full dose do not need a microdosing strategy. The clinical case for sub-label dosing is strongest in people who experience grade 2 or higher nausea at a given step, who have a body mass index <30 and a lower total weight-loss target, or who are transitioning off a higher dose toward a weight-stable maintenance phase.

The Standard Titration Schedule and Where Microdosing Fits

The label titration exists because the half-life of semaglutide is approximately seven days [1], meaning steady-state plasma levels take four to five weeks to stabilize at any dose. Jumping steps compresses the exposure ramp and floods GLP-1 receptors in the area postrema faster than the body can adapt, which is the primary driver of nausea.

A slower-than-label microdosing schedule might look like this for semaglutide:

• Weeks 1 to 6: 0.1 mg weekly
• Weeks 7 to 12: 0.25 mg weekly
• Weeks 13 to 18: 0.5 mg weekly
• Weeks 19 to 24: 1.0 mg weekly
• Week 25 onward: advance to 1.7 mg or 2.4 mg only if weight loss has stalled and GI tolerance is confirmed

This extended 24-week ramp is not in any published guideline; it represents a clinical practice pattern reported by obesity-medicine physicians managing patients with prior GLP-1 intolerance or significant gastroparesis risk. The 2016 AACE/ACE obesity clinical practice guidelines state that "individualization of pharmacotherapy, including dose adjustments based on tolerability and response, is appropriate for all anti-obesity medications" [3], which provides the regulatory justification for slower titration.

For tirzepatide, the equivalent microdosing approach involves holding 2.5 mg for eight to twelve weeks rather than four before stepping to 5 mg. SURMOUNT-1 (N=2,539) showed that even participants randomized to 5 mg tirzepatide, the lowest active arm, lost a mean 15.0% of body weight at 72 weeks compared with 3.1% for placebo [4]. That single data point is the strongest argument for not forcing a reluctant patient to the 15 mg ceiling: sub-maximal doses can be highly effective.

How Semaglutide and Tirzepatide Doses Actually Perform at Each Step

Understanding dose-response relationships helps patients and clinicians decide where to stop titrating, which is the essence of identifying a maintenance dose.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% from baseline at 68 weeks versus 2.4% with placebo (P<0.001) [5]. The trial did not include sub-2.4 mg maintenance arms, but the titration design means all participants spent at least four weeks at 1.0 mg and four weeks at 1.7 mg, giving indirect evidence that some weight loss was occurring long before full dose.

STEP-2 enrolled adults with type 2 diabetes and compared semaglutide 1.0 mg, semaglutide 2.4 mg, and placebo. The 1.0 mg arm produced 9.6% weight loss versus 3.4% placebo at 68 weeks [6]. That 9.6% figure is clinically meaningful and achieved at less than half the ceiling dose, underscoring that many patients may reach their personal weight-loss target before needing 2.4 mg.

STEP-3 combined semaglutide 2.4 mg with intensive behavioral therapy (N=611) and found 16.0% mean weight loss at 68 weeks [7], the highest in the STEP series. Behavioral co-intervention amplified results without requiring a dose increase, a reminder that microdosing combined with structured lifestyle support may produce outcomes comparable to full-dose therapy without the GI burden.

STEP-5 followed participants for 104 weeks on 2.4 mg semaglutide and found 15.2% weight loss was maintained at two years [8], demonstrating that sustained full-dose therapy prevents the regain seen after discontinuation.

For tirzepatide, SURMOUNT-1 showed a clear dose-response: 5 mg produced 15.0%, 10 mg produced 19.5%, and 15 mg produced 20.9% weight loss at 72 weeks [4]. The incremental benefit of 15 mg over 10 mg was approximately 1.4 percentage points of body weight, which may not justify a dose escalation in patients experiencing significant nausea at 10 mg.

SURMOUNT-2, which enrolled adults with type 2 diabetes (N=938), found that tirzepatide 10 mg and 15 mg produced 13.4% and 15.7% weight loss respectively at 72 weeks versus 3.3% placebo [9]. The diabetes context reduces absolute weight loss, but the relative dose-response pattern is similar.

What to Do After a Missed Dose

Missing a weekly GLP-1 injection breaks the steady-state plasma level that drives appetite suppression. How large the clinical consequence is depends on timing.

The Wegovy prescribing information states clearly: if a dose is missed and the next scheduled dose is more than five days away, inject the missed dose as soon as possible. If fewer than five days remain before the next scheduled dose, skip the missed dose entirely and resume on the regular schedule [1]. The same five-day rule applies to Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) [10].

For Zepbound and Mounjaro, the FDA label specifies the same window: administer the missed tirzepatide dose as soon as possible if the next scheduled dose is more than four days away; otherwise skip and resume the regular day [2].

Patients on compounded semaglutide or tirzepatide should follow the same windows because the pharmacokinetics are identical to the branded formulations.

Two practical issues arise with missed doses during microdosing:

First, a patient on a slow titration who misses two consecutive doses may experience return of appetite within seven to ten days as plasma levels drop below threshold. This is not a reason to restart from the lowest dose; the prescriber should reassess current dose level and resume from the last tolerated step unless side effects have completely resolved, in which case dropping one step before resuming is reasonable.

Second, patients who intentionally skip doses to extend a supply of compounded medication are effectively self-imposing a microdose schedule. This practice carries risk because inconsistent plasma levels may worsen rebound hunger and reduce efficacy compared with a deliberate, physician-supervised lower fixed dose taken consistently every seven days.

Weight-Loss Plateaus on GLP-1 Therapy: Causes and Solutions

A plateau on GLP-1 therapy is defined here as fewer than 0.5 lb per week average loss over four or more consecutive weeks after at least twelve weeks of therapy at a stable dose. Plateaus are expected and do not indicate treatment failure.

Three physiological mechanisms drive GLP-1 plateaus. First, as body weight falls, total resting energy expenditure drops by roughly 10 to 15 kcal per kilogram of lost fat mass, so the same dose produces smaller absolute weekly deficits over time. Second, GLP-1 receptor density in the hypothalamus may downregulate with prolonged agonist exposure, blunting the appetite-suppression signal at a fixed dose. Third, adaptive thermogenesis, the metabolic slow-down documented in post-bariatric and post-diet patients, reduces total daily energy expenditure beyond what body-weight reduction alone predicts.

When a patient plateaus, the first question is whether the current dose is truly the ceiling dose or whether there is a step remaining. If a patient on semaglutide 1.0 mg has plateaued after twelve weeks and tolerates the medication well, advancing to 1.7 mg is the indicated move before any other intervention.

If the patient is already at the labeled ceiling and has plateaued, four options exist within the scope of GLP-1 titration:

1. Confirm the dose is being injected correctly and consistently on the same day each week.
2. Assess dietary patterns for energy-density creep, which commonly occurs after six to nine months of therapy as food aversion fades.
3. Consider a structured four-week caloric re-evaluation with a registered dietitian before changing the medication dose.
4. Discuss with the prescribing physician whether switching from semaglutide to tirzepatide is appropriate, given tirzepatide's dual GIP/GLP-1 mechanism and higher ceiling efficacy in SURMOUNT-1 [4].

STEP-8 (N=338) compared semaglutide 2.4 mg head-to-head with liraglutide 3.0 mg and found 15.8% vs. 6.4% weight loss at 68 weeks [11], establishing that switching within the GLP-1 class to a higher-efficacy agent is a clinically validated strategy.

Finding Your Maintenance Dose

The maintenance dose is the lowest weekly dose that keeps body weight within 2 to 3% of your goal weight for at least twelve consecutive weeks without intolerable side effects. It is not automatically the ceiling dose.

STEP-5 data show that 2.4 mg semaglutide sustained 15.2% weight loss at 104 weeks when continued without interruption [8]. However, not every patient needs 2.4 mg to maintain results. A patient who lost 14% of body weight at the 1.7 mg step during titration and has held that loss for eight weeks may be a candidate for remaining at 1.7 mg rather than escalating.

The clearest evidence for what happens when the dose stops comes from SURMOUNT-4. Participants who completed 36 weeks of tirzepatide at their maximum tolerated dose (up to 15 mg), then were randomized to placebo, regained a mean 14.8% of body weight by week 88 [12]. Those who remained on tirzepatide maintained their loss and lost an additional 5.5%. This finding, replicated across the STEP series and SELECT cardiovascular outcomes trial [13], means that stopping the medication is the main driver of regain, not dose reduction.

The Endocrine Society and AACE both classify obesity as a chronic disease requiring long-term pharmacotherapy in most patients, consistent with treating hypertension or type 2 diabetes as ongoing conditions rather than episodic ones [3].

A practical maintenance-dose titration protocol, used by some obesity-medicine practices, involves the following steps once goal weight is reached:

• Hold current dose for twelve weeks and confirm weight stability (within 2% of goal).
• Drop one dose step (for example, from 2.4 mg to 1.7 mg semaglutide) and reassess at eight weeks.
• If weight remains stable within 2%, hold at the lower step.
• If weight increases by more than 3% of total body weight, return to the prior effective dose and hold indefinitely.

This stepwise de-escalation has not been tested in a randomized controlled trial as of the time of writing. It reflects emerging clinical practice rather than label guidance, and any individual patient should follow the recommendation of their prescribing physician.

The SELECT Trial and Why Maintenance Dosing Matters Beyond Weight

SELECT (N=17,604) assigned adults with pre-existing cardiovascular disease and a body mass index >27 but without diabetes to semaglutide 2.4 mg or placebo. At a mean follow-up of 39.8 months, semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [13]. The cardiovascular benefit was independent of the degree of weight loss, suggesting that GLP-1 receptor agonism itself, not just the downstream weight change, drives risk reduction.

This finding matters for microdosing decisions because a patient who stabilizes weight at 1.0 mg semaglutide may still be receiving meaningful cardiovascular protection even if they have not reached the 14.9% weight-loss benchmark from STEP-1. Dose decisions should therefore account for both metabolic and cardiovascular endpoints, not weight loss alone.

Compounded GLP-1 Medications and Microdosing Precision

Branded auto-injector pens (Wegovy, Zepbound, Ozempic, Mounjaro) deliver fixed doses per click. A Wegovy pen cannot dispense 0.1 mg or 0.375 mg. Compounded semaglutide and tirzepatide, drawn from multi-dose vials with an insulin syringe, allow any dose the prescriber writes.

The FDA has stated that compounded versions of semaglutide and tirzepatide are not FDA-approved and carry different sterility and potency assurance profiles compared with branded products [1][2]. Patients using compounded formulations for microdosing must obtain them from a 503A or 503B-licensed compounding pharmacy and should have the concentration verified by their prescribing physician before drawing any dose.

One practical risk of compounded microdosing is calculation error. A vial labeled "5 mg/mL" requires 0.02 mL per 0.1 mg dose, a volume that approaches the resolution limit of a standard insulin syringe. Prescribers should specify the exact draw volume in the prescription and provide written instructions to the patient.

Monitoring Parameters During Microdosing

Regardless of the dose strategy, certain monitoring checkpoints apply across all GLP-1 titration approaches.

Thyroid surveillance is relevant because semaglutide and tirzepatide carry an FDA boxed warning for thyroid C-cell tumors based on rodent data. The labels contraindicate use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1][2]. Baseline thyroid function tests are reasonable before starting therapy, though routine calcitonin monitoring is not currently mandated by the labels.

Gastrointestinal monitoring during any dose escalation should assess nausea severity on a structured scale at each visit. Nausea rated 7 or above on a 10-point scale at a given dose step for two or more weeks is a signal to hold the current dose rather than advance.

Renal function should be checked at baseline and at six months in patients with pre-existing chronic kidney disease, as acute kidney injury secondary to dehydration from vomiting has been reported in post-market surveillance [1].

Heart rate increases of 10 to 20 beats per minute are documented in clinical trials at full semaglutide dose [5]. Patients with pre-existing tachycardia or atrial fibrillation should have resting heart rate checked at each visit during up-titration.